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SBackground: Venovenous extracorporeal membrane oxygenation (VV-ECMO) is used in refractory acute re-
spiratory distress syndrome where lung recovery is the primary goal. For its achievement, adequate extracorpo-
real blood flow and a maximal separation between oxygenated (inflow) and deoxygenated (outflow) blood flow
are essential for reducing the recirculation phenomenon. We introduce the c-configuration, a new cannulation
strategy for VV-ECMO.
Patients andMethods:We report our experiencewith 30 VV-ECMO consecutive patients: in 16 patients (group
NS) we applied the c-configuration, which consists of a particular right atrial cannula arrangement and a self-
made modified inflow cannula, consisting of an outflow multihole venous cannula that was inserted percutane-
ously through the right femoral vein, into the right atrium, just below on the superior vena cava, and a self-made
modified curved inflow cannula (inserted percutaneously through the right internal jugular vein) that, in its ter-
minal segment, permitted the tip to be positioned close to the tricuspid valve. In 14 patients (group C) we applied
the standard femoro-jugular VV-ECMO 2-cannula setting. In both groups, efficacy of blood oxygenation was
obtained by gas–blood analysis, by blood samples obtained at arterial, central venous, and pulmonary artery
lines, and by ECMO inflow and outflow lines. The recirculation fraction was obtained by a specific bedside
formula.
Results: No differences were noted between groups regarding the pre-ECMO patient characteristics. No com-
plications during cannulation were recorded. In group NS, on-ECMO time, post-ECMO mechanical ventilation
time, and ECMO overall results were significantly better than in group C. During high-flow VV-ECMO, pulmo-
nary and systemic arterial oxygen saturation and arterial oxygen tension were significantly higher in group NS,
and blood recirculation fraction was significantly lower.
Conclusions: Our data indicate that c-configuration can be safe, feasible, and more effective than conventional
VV-ECMO. It permits near complete drainage of the desaturated blood and a preferential oxygenated blood
inflow toward the tricuspid valve, resulting in a significant reduction of recirculation, thereby improving the
patient’s oxygenation. Our innovative strategy reduces on-ECMO and post-ECMO mechanical ventilation
time, gives a faster and better pulmonary recovery, improves survival, and can reduce hospital costs. (J Thorac
Cardiovasc Surg 2011;142:1197-204)Video clip is available online.
Severe acute respiratory failure (SARF) is characterized by
a profound deterioration in oxygenation and/or ventilation
despite maximal supportive respiratory therapy.1 Although
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The Journal of Thoracic and Cardevastating consequences. In the past few years, attempts
have been made to optimize lung-protective ventilation.3-5
Ventilator lung injury (VILI) is an important limiting factor
of lung recovery2,6; therefore, some patients with refractory
SARF require unconventional mechanical ventilation to
prevent additional lung injury, life-threatening hypoxemia,
and death.
Extracorporeal membrane oxygenation (ECMO) was
first introduced clinically in 1972.7 Significant controversy
surrounds the use of ECMO in the nonneonatal popula-
tion.8-10 The Conventional Ventilation or ECMO for
Severe Adult Respiratory Failure (CESAR) study11 demon-
strated an improved outcome with ECMO support in adult
patients with seemingly irreversible SARF. In the clinical
setting, venovenous ECMO (VV-ECMO) allows ‘‘pulmo-
nary rest’’ and recovery but is limited by the ‘‘recirculation
phenomenon.’’8-10
Since 2007 we have been developing an extracorporeal
life support program. In isolated patients with adultdiovascular Surgery c Volume 142, Number 5 1197
Abbreviations and Acronyms
BRF ¼ blood recirculation fraction
CESAR ¼ Conventional ventilation or ECMO for
Severe Adult Respiratory failure
CO ¼ cardiac output
ECMO ¼ extracorporeal membrane oxygenation
FIO2 ¼ inspired oxygen fraction
PaCO2 ¼ arterial carbon dioxide tension
SVC ¼ superior vena cava
SARF ¼ severe acute respiratory failure
VILI ¼ ventilator lung injury
VV-
ECMO
¼ venovenous extracorporeal membrane
oxygenation
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Srespiratory distress syndrome, we used the VV-ECMO with
a high flow strategy by setting the ventilator to the most
protective modality and allowing lung rest,11 reducing
VILI, and thus a producing a faster lung recovery.4,5 In
cases in which there was limited blood drainage and,
consequently, limited VV-ECMO flow in respect to patient
cardiac output (CO), we found inadequate blood separation
between the venous blood drainage and the inflow arterial-
ized blood returned by ECMO augmenting the amount of
the blood recirculation fraction (BRF).
On the basis of its intrinsic setting, BRF between outflow
and inflow cannulas remains a clinical obstacle, whereas
VV-ECMO high blood flow per se impairs systemic oxy-
genation and contradicts the primary purpose of this prac-
tice. The efficacy of VV-ECMO support can be limited
even when higher flow speeds are used. Various cannula set-
tings have been proposed to resolve this problem.12,13 To
date, none has proven sufficient clinical data in terms of
radically resolving these problems.
In August 2007, we developed a novel strategy, the
‘‘c-configuration,’’ to obtain an optimal extracorporeal
blood oxygenation.
The aim of this study was to evaluate the feasibility,
safety, efficacy, and efficiency of the c-configuration in
comparison with the classic 2-cannula VV-ECMO.
PATIENTS AND METHODS
Patient Characteristics
From August 2007 to October 2010, 30 patients with isolated (adequate
cardiac performance) refractory SARF were treated with VV-ECMO. All
patients had unsuccessful maximal conventional ventilator and medical
therapy. The protocol was approved by the central institutional review
board. All patients or their relatives signed informed consent forms.
We applied the Extracorporeal Life Support Organization indications
and contraindication to VV-ECMO [http://www.elso.med.umich.edu/
Guidelines.html].
As previously reported,14 our ECMO team caring for these patients be-
lieved that the patients would not survive without ECMO. All of our pa-
tients had a partial pressure of oxygen less than 60 mm Hg and an1198 The Journal of Thoracic and Cardiovascular Suroxygenation index of almost 40. Additionally, all members of the team be-
lieved that the patients had a reasonable chance of survival if the respiratory
illness could be supported. Exclusion criteria included an irreversible
underlying pulmonary injury, mechanical ventilation at high settings
(inspired oxygen fraction [FIO2]>0.9, end inspiratory plateau pressure>
30 cm H2O) for 7 days or more, ongoing bleeding, central nervous system
hemorrhage, or the coexistence of any condition that would prevent sys-
temic anticoagulation.
Patients were divided randomly into 2 groups: groupNS (n¼ 16 patients)
underwent the c-configuration and group C (n ¼ 14 patients) underwent
a standard 2-cannula femoro-jugular VV-ECMO.15 Patients’ demographics
and clinical characteristics are elaborated in Table 1.
Cannulation Strategy and VV-ECMO Setting
All VV-ECMOprocedures were performed at the bedside. In all patients
we used arterial and venous bio-coated cannulas. Both inflow and outflow
cannulas were inserted by the Seldinger techniques and cannula position
was assisted with transesophageal echography guidiance. The sizes of can-
nulas were related to patient anatomic features. CO and mixed venous ox-
ygen saturation were continuously recorded. The oxygenator FIO2 was set
to 100% and gas flowwas set to 1:1 with blood flow. Later on it was titrated
to the patient’s arterial carbon dioxide tension (PaCO2).
In group C (14 patients), we applied a standard 2-cannula venovenous
technique. In brief, deoxygenated blood was drained from the right atrium
through a cannula inserted percutaneously into the right femoral vein. The ox-
ygenated blood was returned via a short cannula inserted in the right internal
jugular vein just distal to the superior vena cava (SVC).
In goup NS (16 patients), we applied a novel cannulation setting, the
c-configuration: this is an original 2-cannula VV-ECMO cannulation
strategy, allowing a high-flowECMOand reducingBRF by inducing a pref-
erential oxygenated blood flow directly through the tricuspid valve.
In detail, to permit a high-flowVV-ECMO for near complete extracorpo-
real blood oxygenation, an outflow multihole venous cannula was inserted
percutaneously through the right femoral vein into the right atrium, just
below the SVC: this position maximizes desaturated blood draining, inter-
cepting near total blood returned from both venae cavae.
For the oxygenated blood reinfusion, we used a self-made and modified
long arterial inflow cannula (23 cm). After removal of the mandrel, it ac-
quired a 60 angle in its terminal segment, and after atrial insertion via
the right internal jugular vein, the tip could be positioned close to the tri-
cuspid valve. This cannula configuration allowed preferential oxygenated
blood flow through the tricuspid valve to the right ventricle and, as a result,
to the pulmonary and systemic circulations, reducing dramatically the
VV-ECMO recirculation phenomenon.
The inflow cannula was modified by making a 60 curvature in its distal
third by a three-five 3–0 polypropylene, 0.5/1 cm large, single stitch that
was knotted over the tip and terminated after 3 to 4 cm with a soft left ro-
tation (Figure 1). Selection of a monofilament stitch was favorable as it is
less prone to infection and coagulation activation. The tip orientation was
correlated to the female Luer-Lok of the cannula. After a cannula linear res-
toration with remandrination, it was inserted in the right internal jugular
vein and delivered to the right atrium with the tip near the tricuspid valve
(Figure 2). Correct cannula position was verified with transesophageal
echocardiography. Chest radiography showed the curvature of the radi-
opaque inflow cannula (Figure 3).
Ventilation Strategy, Pulmonary Care, Patient
Monitoring, and BRF Calculation
Our ventilation strategy during ECMO was as follows: once maximal
ECMO flow was achieved, ventilation was gradually reduced. The target
for optimal patient oxygenation was considered to be an arterial oxygen sat-
uration (SaO2) of 95% ormore. Protective ventilator settingswere as follows:
pressure control, peak inspiratory pressure less than 30 cm H2O (better if
<25 mm Hg), and positive end-expiratory pressure between 10 and 15 cmgery c November 2011
TABLE 1. Pre-ECMO group NS and group C data. No statistical
differences are found in patient characteristics, SARF etiology,
pulmonaryfunctional status, or laboratoryandarterial bloodgasanalysis
Variable Group NS Group C
P
values
Patients (N) 16 14
Male (N) 13 (81.25) (78.57) .818
Age (y) 42.3  21.5 43.8  24.7 .862
BSA (m2) 1.92  0.21 1.85  0.24 .838
Renal substitution therapy 2 (12.5) 2 (14.3) .683
SARF etiology
Bacterial pneumonia 8 (50) 8 (57) .695
Viral pneumonia 4 (25) 3 (21.5) .839
Trauma/postoperation 2 (12.5) 2 (4.3) .693
Other 2 (12.5) 1 (7.15) .902
Mechanical ventilatory setting
Ventilation support (d) 6.78  1.8 6.45  2.2 .655
FIO2 0.99  0.07 0.98  0.08 .717
PIP (cm H2O) 44.3  7.3 41.8  9.5 .422
PEEP (cm H2O) 13.2  3.5 12.4  2.7 .494
Pulmonary compliance
(mL/cm2)
11.3  5.4 12.5  6.1 .573
Oxygenation index 63.2  11.8 59.1  10.5 .326
Murray score 3.42  0.45 3.29  0.53 .473
Laboratory values
WBC count (N*1000/ml) 23.5  9.3 22.8  6.9 .819
Hgb (g/dL) 12.2  3.6 12.5  4.1 .832
Platelet count (N $ 1000/mL) 201.8  43.7 220.5  54.8 .307
Serum creatinine (mg/dL) 0.985  0.12 0.96  0.23 .707
Arterial blood gas values
pH 7.25  0.03 7.27  0.05 .188
PaO2 (mm Hg) 57.8  2.1 58.7  2.3 .272
PaCO2 (mm Hg) 80.8  10.4 76.2  12.8 .287
SaO2 (%) 76.3  5.2 78.4  6.5 .334
PaO2/FIO2 ratio 0.578  0.021 0.587  0.023 .272
Time on ECMO (h) 227.9  92.7 314.7  102.7 .022
VV-ECMO successful 16 (100) 9 (64.2) .044
Post-ECMO mechanical
ventilation (d)
2.8  1.6 4.7  3.2 .048
ICU discharge survival 14 (87.5) 8 (57.14) .058
Hospital discharge survival 14 (87.5) 8 (57.14) .058
Cause of death
Sepsis 1 1
MOF 4
Cerebral death 1 1
Figures in parentheses represent percentage values. Values are mean  standard de-
viation. P<.05 is the significant difference. ECMO, Extracorporeal membrane oxy-
genation; SARF, severe acute respiratory failure; BSA, body surface area; FIO2,
fraction of inspired oxygen; PIP, peak inspiratory pressure; PEEP, positive end-
expiratory pressure; WBC, white blood cells; Hgb, hemoglobin concentration; PaO2,
arterial oxygen tension; PaCO2, arterial carbon dioxide tension; SaO2, arterial oxygen
saturation; VV, venovenous; ICU, intensive care unit; MOF, multiorgan failure.
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SH2O, depending on pressure/volume curves. Controlled respiratory fre-
quency was reduced to 4 to 10 breaths/min. FIO2 was reduced to 0.5 or lower,
whenever possible.2 ECMO flow was adjusted to keep arterial saturation at
95% or more with normal carbon dioxide levels. Patients were treated as
soon as possible with continuous positive airway pressure or spontaneous
breathing. Lungs were evaluated periodically by computed tomographicThe Journal of Thoracic and Carscan, chest X-ray, and daily lung ultrasound examinations.14 Blood was
transfused when required to reach hemoglobin levels of 11 to 13 mg/dL. If
sufficient lung rest settings were still not achieved within 2 to 3 days, stan-
dard perfusion was converted to modified perfusion: in 2 group C patients
venoarterial ECMO configuration was applied.
A Swan-Ganz catheter (Edwards LifeSciences, Irvine, Calif) was in-
serted to measure CO, pulmonary vascular resistance, pulmonary blood
gas analysis, and continuous oxygen saturation in the pulmonary artery.
Functional oxygen saturation was monitored continuously as well. Central
venous blood gas analysis was obtained from a central venous catheter (tip
positioned in the distal portion of the SVC). Circuit monitors included pre-
oxygenator and postoxygenator blood gas analysis and pressure.
As for ECMOweaning and trial off, once pulmonary function improved,
verified by increased pulmonary compliance and improved chest radiograph
and computed tomography, the extracorporeal blood flow was reduced (us-
ing steps of 10% of maximal flow each 6–8 hours). During this ECMO re-
duction, monitoring central venous and arterial oxygen saturation was
essential. When the ECMO flow was reduced to such a low level that it
no longer contributed substantially to the gas exchange (1.5 L $ m2 $
min1), a trial off was indicated. If lung function was adequate at the accept-
able ventilator settings for an hour or more, the patient was ready for dec-
annulation.
BRF is defined as the portion of blood that has just been oxygenated
within the ECMO circuit oxygenator and will flow directly from the reinfu-
sion site and be taken by the venous drainage cannula, instead of being de-
livered to the patient’s circulation. Several complex and invasive methods
were introduced for RBF calculation.12,13,15 For BRF evaluation, we
applied a simple bedside formula, using evaluation of blood oxygen
saturation obtained from different sites according to the formula:
BRF ð%Þ ¼ ðSpreOxy Scvo2=SpostOxyScvo2Þ3100
where SpreOxy is the oxygen saturation level of the blood entering the ox-
ygenator, SpostOxy is the oxygen saturation level of the blood exiting the
oxygenator, and ScvO2 is cerebral oxygen saturation. For cerebral oxygen
saturation, ideally we would need to use the mixed venous oxygen satura-
tion, but is impossible to measure the true mixed venous oxygen saturation
during VV-ECMO. It was obtained by sampling blood from the SVC prox-
imal portion.
ECMO Equipment and Anticoagulation Strategy
The ECMO equipment used (pump, oxygenator, and cannulas) were all
bio-coated.
Heparin infusion, applied directly within the ECMO circuit, with a pre-
oxygenator stopcock, wasmonitored and titrated every 2 hours by a bedside
measurement of activated partial thromboplastin time. Anticoagulation
was maintained at a mean (standard deviation) of 55.9 (7.6) seconds for
all patients. In case of renal replacement therapy during the ECMO proce-
dure, a continuous venovenous hemodiafiltration circuit was assembled di-
rectly into the ECMO circuit (aspiration and restitution on prepump line).Evaluation of c-Configuration Efficiency and
Efficacy
All group NS and group C patients were evaluated to determine the
efficiency and efficacy of different types of VV-ECMO in the systemic
oxygenation.
Under the same ECMOflow (equal to 80%CO) and protective mechan-
ical ventilation as previously reported, blood samples were drawn from the
patient’s radial artery, pulmonary artery, and central venous preoxygenator
and postoxygenator lines. All measurements were repeated 3 times. Any
individual measurement at each site that differed from the other 2 measure-
ments by more than 10% was discarded and another measurement was
made. The results were averaged for subsequent analysis. For all patients,
BRF was calculated as well. All data are reported in Table 1.diovascular Surgery c Volume 142, Number 5 1199
FIGURE 1. The ‘‘customized’’ arterial cannula. A, The nonmodified cannula: with the mandrel in place (left) and with the mandrel removed (right). B, The
self-made modified arterial cannula: with the mandrel in place (left) and with the mandrel removed (right). C, The customized cannula tip (particular): with the
mandrel in place (left) and with the mandrel removed (right). The arrows indicate the polypropylene single stitches making a 60 curvature with a soft left
rotation.
FIGURE 2. The c-configuration modified VV-ECMO cannulation. Blood is drained from the two venae cavae (superior [SVC] and inferior [IVC]) by
a multihole cannula placed, through the right femoral vein, to the right atrium with the tip just below on the SVC. Arterialized blood is returned to the right
atrium through the self-mademodified arterial cannula (23 cm long) placed through the right internal jugular vein with the tip toward the tricuspid valve (TV).
Apolypropylene stitchwas used tomake 4 consecutive bites over the distal 3-4 cmof the arterial cannula to create the desired curvature and a soft left rotation.
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FIGURE 3. Plain chest x-ray film shows the lazy curvature of the in flow
cannula from the right neck base toward the right ventricle. The cannula tip
(*) and the tricuspid valve plan (continuous line) are marked. The drawing
cannula is located in right atrium below the superior vena cava.
Bonacchi et al Evolving Technology/Basic ScienceStatistical Analysis
Wilcoxon tests were used to compare continuous variables between the
2 groups, whereas Pearson c2 tests were used for categorical variables. All
data collection and statistical analysis was performed using SPSS version
18 software (SPSS Inc, Chicago, Ill). Results are presented as mean values
 standard deviation unless otherwise noted.E
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As reported in Table 1, there were no significant differ-
ences between the 2 groups in terms of demographic data,
SARF etiology, associated pathologic conditions, body
mass index, and hemocoagulative and blood gas analysis
data. No differences were found between groups in immedi-
ate pre-ECMO evaluation, duration of mechanical ventila-
tion support (6.78  1.8 days vs 6.45  2.2 days; P ¼ .45),
and pulmonary functional status: pulmonary compliance,
oxygen index,Murray score, and ventilator settingwere sim-
ilar between groups (P>.05 for all data). Laboratory values
and arterial blood gas values were similar as well. No com-
plications were reported during insertion of VV-ECMO
cannula in group NS or in group C patients.
Minor bleeding, owing to heparin infusion, was the only
complication during ECMO time: 3 patients in group C and
2 in group NS (P>.05) needed blood transfusion for pro-
longed oropharyngeal or cannulation site bleeding.
As reported in Table 1, ECMO timewas significantly lon-
ger in group C than in group NS (227.9  92.7 hours vs
314.7  102.7 hours; P< .0215). Successful VV-ECMO
is intended as the oxygenation target of at least ‘‘systemic
arterial oxygen saturation’’  95%, reached with sufficient
protective pulmonary ventilation, the possibility to wean
ECMO with pulmonary function recovery, and survival of
more that 48 hours without SARF relapse. This result wasThe Journal of Thoracic and Carobtained in all NS group patients and in only 9 (64.2%) C
group patients (P ¼ .044). In fact, in 1 group C patient,
ECMO was converted (after 18 hours) to venoarterial con-
figuration to obtain a sufficient systemic blood oxygenation,
and in 4 other patients no sufficient pulmonary recovery was
obtained. After ECMO discontinuation, the time of me-
chanical ventilation required was significantly shorter in
group NS (2.8  1.6 days vs 4.7  3.2 days; P ¼ .048).
The intensive care unit discharge and hospital discharge
survivals were better in group NS (87.5% vs 57.14%;
P ¼ .058, respectively), although the difference did not
reach a statistical significance. The cause of death is shown
in Table 1 for all nonsurvivors. In 4 group C patients the
cause of death was irreversible pulmonary fibrosis and mul-
tiple organ dysfunction, in 1 other (a 64-year-old woman)
subarachnoid hemorrhage, and in a 54-year-old man sys-
temic secondary infection owing to Aspergillus appeared
7 days after ECMO discontinuation.
In group NS, causes of death were cerebral death second-
ary to severe traumatic brain injury in a 19-year-oldman and
a multiresistant Pseudomonas-related sepsis in a 48-year-
old man. In these 2 patients, after brain death was confirmed
multiple organ donations were accomplished.
Assessment of VV-ECMO started after patient parame-
ters stabilized (mean time ¼ 7.48  5.8 hours and 9.59 
6.2 hours in groups NS and C, respectively; P ¼ .345). At
VV-ECMO flow equal to 80% of the patient’s CO, the
c-configuration seemed to guarantee a better oxygenation
and a reduction of BRF. The detailed results are shown in
Table 2.
During high-flow VV-ECMO, pulmonary, systemic arte-
rial oxygen saturation, and arterial oxygen tension were sig-
nificantly higher in group NS patients (97.6 1.2 vs 91.2
3.2; P<.001; 98.5  1.5 vs 95.7  1.67; P ¼ .0063; and
97.8  12.8 vs 85.3  19.5; P ¼ .044; respectively). To
reach a systemic arterial oxygen saturation of 95% or
more, the group C ventilator setting was necessarily less
protective. Significant differences between groups were
noted in terms of FIO2, minute volume, tidal volume, and in-
trapericardial pressure setting (25.7  9.7 vs 37.9  11.6;
P<.0001;765.6  154.3 vs 1858.8  534.65; P<.0001;
95.7  56.8 vs 154.9  98.7; P ¼ .0395; and 22.3  4.6
vs 28.7 5.1; P¼ .0012, respectively). In group C, the pul-
monary residual function employment and contribution are
essential to obtain the desired level of oxygenation: the im-
provement in oxygen saturation and partial pressure in the
radial artery versus the pulmonary artery is significant
(95.7  1.67 vs 91.2  3.2 [P ¼ .0001] and 85.3  19.5
vs 83.8  14.7 [P ¼ .0487], respectively), while not
in group NS (98.5  1.5 vs 9 7.6  1.2 [P ¼ .071] and
97.8  12.8 vs 97.3  10.3 [P ¼ .904], respectively). The
difference in oxygen content in the pulmonary artery was
significantly higher in the c-configuration than in the con-
ventional configuration (17.56  1.23 vs 16.09  1.45diovascular Surgery c Volume 142, Number 5 1201
TABLE 2. Evaluation of efficacy and efficiency of patient oxygenation,
oxygen delivery, and reduction of BRF of VV-ECMO using
c-configuration versus conventional 2-cannula configuration.
Reported oxygenation data are obtained at the same ECMO flow
(equal to 80% of patient’s CO) and ventilator setting to achieve an
SO2  95% in radial artery
Parameters Group NS Group C
P
value
Ventilator setting
FIO2 25.7  9.7 37.9  11.6 .004
MV (mL) 765.6  154.3 1813.9  534.6 <.0001
TV (mL) 95.7  56.8 164.9  98.7 .024
Breaths/min 8  3.8 11  5.2 .079
PEEP (cm H2O) 10.4  2.6 12.3  4.3 .1484
PIP (cm H2O) 22.3  4.6 28.7  5.1 .0011
Hemodynamic
CO (L/min) 8.2  1.7 7.4  1.53 .19
BSA (m2) 1.92  0.21 1.85  0.24 .401
CI (CO/BSA L
$ min–1 $ m–2)
4.27  0.93 4  0.85 .415
VV-ECMO setting
ECMO flow (L/min)
Equal to 80%
of CO
6.56  0.9 5.92  1.12 .094
ECMO gas flow
(L/min)
7.2  1.3 6.5  1.8 .228
ECMO FIO2 100% 100%
Blood gas analysis values
Radial artery blood samples
pH 7.442  1.3 7.45  1.7 .988
PCO2 (mm Hg) 35.6  2.8 33.4  4.6 .119
PO2 (mm Hg) 97.8  12.8 85.3  19.5 .044
Hgb (g/dL) 12.4  3.5 12.7  4.6 .84
SO2 (%) 98.5  1.5 95.7  1.67 .0063
Pulmonary artery blood samples
pH 7.439  0.12 7.425  0.196 .813
PCO2 (mm Hg) 36.1  4.3 39.8  6.2 .065
PO2 (mm Hg) 97.3  10.3 83.8  14.7 .0065
Hgb (g/dL) 12.5  2.7 12.3  3.6 .8635
SO2 (%) 97.6  1.2 91.2  3.2 <.001
Central venous samples
pH 7.31  0.87 7.28  1.1 .934
PCO2 (mm Hg) 50.9  2.5 51.2  3.2 .775
PO2 (mm Hg) 43.1  3.8 40.2  5.3 .093
Hgb (g/dL) 12.3  2.9 11.7  3.8 .628
ScvO2 (%) 77.4  4.7 75.2  9.2 .408
Preoxygenator samples
pH 7.36  0.93 7.37  1.43 .982
PCO2 (mm Hg) 49.8  2.8 46.3  4.8 .019
PO2 (mm Hg) 42.7  4.2 48.6  5.7 .003
Hgb (g/dL) 12.1  3.1 12.4  3.5 .805
SO2 (%) 78.6  2.1 82.5  7.2 .047
Postoxygenator samples
pH 7.49  0.09 7.485  0.12 .897
PCO2 (mm Hg) 30.2  8.45 31.7  9.2 .645
PO2 (mm Hg) 478  87.8 453  91.4 .452
Hgb (g/dL) 12.1  2.8 12.4  3.2 .876
(Continued)
TABLE 2. Continued
Parameters Group NS Group C
P
value
SO2 (%) 100 100 1
BRF (%)
(PreOxyO2ScvO2)/
(PostOxyO2
ScvO2) $100
5.31  3.68 29.43  8.96 <.0001
Values are mean  standard deviation. P<.05 is significantly different. BRF, Blood
recirculation fraction; VV-ECMO, venovenous extracorporeal membrane oxygena-
tion; CO, cardiac output; SO2, oxygen saturation; FIO2, fraction of inspired oxygen;
MV, respiratory minute volume; TV, tidal volume;PEEP, positive end-expiratory pres-
sure; PIP, peak inspiratory pressure; CO, cardiac output; BSA, body surface area; CI,
cardiac index; PaCO2, arterial carbon dioxide tension; PO2, oxygen tension; Hgb, he-
moglobin concentration; SO2, oxygen saturation; PO2, carbon dioxide tension; ScvO2,
central venous oxygen saturation.
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S[P ¼ .0315], respectively) in which pulmonary function is
necessary (with an increase in blood oxygen content signif-
icant from 16.09  1.45 to 17.38  1.82 [P ¼ .048] after
pulmonary transit) to obtain a radial artery oxygen content
similar to group NS (17.59  1.76 vs 17.38  1.82
[P ¼ .762], respectively). Moreover, in group NS, at the
same elevated flow levels, BRF was significantly lower
and more uniform than that of group C (5.3  3.6 vs
29.43  8.9 [P< .0001], respectively). Regarding carbon
dioxide removal, both cannula configurations are similar
in efficacy and efficiency.DISCUSSION
Advances in mechanical ventilation and new ventilation
strategies designed to promote optimal ventilation and per-
fusion while sparing lung parenchyma from barotraumas
have been applied formore than 10 years, as SARFmortality
remains as high as 66%.2,6 Highmortality is caused bymany
complications, such asmultiple-organ failure, sepsis, stroke,
myocardial infarction, and progressive lung injury. All occur
from the underlying disease or from prolonged positive-
pressure mechanical ventilation and high-concentration
oxygen toxicity with consequent irreversible parenchyma
injury. Parenchymal injury is the principal means of failure
in these patients.1-4,6 SARF patients may benefit from
VV-ECMO support and from ‘‘pulmonary rest’’ setting by
reduction of ventilatory pressure, oxygen concentration,
and as a consequence significant reduction of VILI and im-
provement of pulmonary recovery. Careful selection of pa-
tients who have had unsuccessful conventional ventilator
therapy and the application of ECMO earlier in the disease
process have likely affected outcome: it is important to
limit lung injury both before and during ECMO support to
maximize the chance of recovery.16,17 Notwithstanding the
documented success of non-adult ECMO for SARF
(survival is 71%–88%), significant controversy remains
over the application of ECMO.3,5,8-10,14,18,19 Different
experimental20-23 and clinical4,24 reports show that VILIgery c November 2011
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consequences, probably owing to inflammatory mediators
delivered from the damaged lung when high-pressure me-
chanical ventilation is continued.21 During ECMO, obtain-
ing an optimal blood oxygenation level is possible only if
the VV-ECMO technique permits it: our new cannula
setting, the c-configuration, reduces recirculation and per-
mits a very high ECMO flow related to the patient’s CO,
avoiding invasive surgical methods, which are to date the
only methods that permit similar results.18,25 Although
percutaneous VA-ECMO permits a higher and more consis-
tent oxygen delivery, VV-ECMO reduces invasiveness and
major complications related to arterial cannulation, im-
paired cardiac performance, decreased coronary and cere-
bral oxygen transport and autoregulation, altered regional
blood flow to vital organ, increased pulmonary resistance,
and more.3,8,10,16
Sufficient blood oxygenation with VV-ECMO is more dif-
ficult to achieve in the adult population than in the pediatric
population. Many problems arise, such as recirculation,
high patient CO, limited use of double-lumen cannulas, and
their flow limits.13,18,19 In high-flow VV-ECMO, recircula-
tion plays a central role in limiting oxygen delivery to the
patient. Different factors influence recirculation (eg, cardiac
function, tricuspid valve regurgitation, and VV-ECMO
flow); however, the relative positions of outflow and inflow
cannulas are itsmajor determinants.Nocomplications related
to cannula positioningwere registered during our experience.
From August 2007 to October 2010, we have prospec-
tively enrolled 30 consecutive patients. In all reported pa-
tients the risk of mortality was 80% to 100% if
conventional treatment was continued.19-21 Total survival
was equal to 73.3%, comparable with other published
studies.8-11,16,19 In group NS the survival was 87.5%, and
if there is no statistically significant difference from group
C survival (57.14%; P ¼ .058) the better outcome could
be related to better patient systemic oxygenation, reduced
BRF, and the consequent possibility of a very protective
ventilatory strategy and a real pulmonary rest. Our data
seem to confirm that c-configuration is capable of inducing
a more prompt and more complete pulmonary recovery
(with a reduction of on-ECMO time and ECMO-related
complications) and consequently reduces the incidence of
pulmonary fibrosis. Moreover, our data demonstrate that
at equal ECMO flow (80% of the patient’s CO), our new
c-configuration strategy permitted reduction in recirculation
fraction, a higher systemic arterial oxygen tension, and
a lower ECMO flow to obtain sufficient patient oxygenation
(reducing the side effects of extracorporeal circulation, such
as hemolysis, thrombocytopenia, and inflammation).
CONCLUSIONS
Treating patients who have SARF with VV-ECMO has
become an important tool in advanced critical care medi-The Journal of Thoracic and Carcine. Nevertheless, it is at times ineffective, especially in
the presence of a high BRF.
We have introduced a novel but simple strategy for opti-
mizing VV-ECMO oxygenation, the c-configuration, con-
sisting of a particular arrangement of the intra-atrial
cannula position and an original self-made inflow cannula
modification. This new strategy allowed higher separation
between inflow and outflow blood flows, thus significantly
reducing recirculation and greatly increasing systemic oxy-
gen saturation and delivery. Venoarterial ECMO and other
invasive and hazardous surgical procedures were avoided.
No major complications related to the modified inflow can-
nula were observed, including arrhythmias.
In our opinion, the c-configuration allows very protective
ventilator settings when trying to achieve lung rest, avoid-
ing overall VILI, and consequently improves patient
outcomes and seems to reduce ECMO time, time to pulmo-
nary recovery, intensive care unit stay, and hospital costs.References
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